1. ALLA AKTIER
  2. NYHETER
  3. MENDUS

Mendus

Nyheter Mendus Nyheter alla bolag

Invitation to presentation of Mendus’ year-end report for 2024

Mendus AB (“Mendus” publ; IMMU.ST), will publish its year-end report for 2024 on Thursday 13 February at 08.00 CET. The company will host a live presentation and business update on the same day at 08.30 CET. The presentation will be held in English and includes a Q&A session

Date and time: Thursday 13 February at 08.30 CET

The presentation can be followed via:
https://mendus.events.inderes.com/q4-report-2024/register

If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://conference.inderes.com/teleconference/?id=5004794

For more information, please contact:
Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com

About Mendus AB (publ)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/

Attachments
Invitation to presentation of Mendus’ year-end report for 2024

Datum 2025-02-10, kl 08:00
Källa MFN
Bifogade filer
Invitation to presentation of Mendus’ year-end report for 2024
Affiliate
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet